Literature DB >> 26539938

Primary and Revision Posterior Lumbar Fusion Have Similar Short-Term Complication Rates.

Bryce A Basques1, Pablo J Diaz-Collado, Benjamin J Geddes, Andre M Samuel, Adam M Lukasiewicz, Matthew L Webb, Daniel D Bohl, Junyoung Ahn, Kern Singh, Jonathan N Grauer.   

Abstract

STUDY
DESIGN: Retrospective cohort study.
OBJECTIVE: To compare short-term morbidity for primary and revision posterior lumbar fusions. SUMMARY OF BACKGROUND DATA: Revision lumbar fusions are unfortunately relatively common. Previous studies have described an increased risk of postoperative complications after revision lumbar fusion; however, these studies have been limited by small sample sizes, poor data quality, and/or narrow outcome measures. There is a need to validate these findings using a high-quality, national cohort of patients to have an accurate assessment of the relative risk of revision posterior lumbar fusions compared with primary lumbar fusion.
METHODS: The prospectively-collected American College of Surgeons National Surgical Quality Improvement Program database was used to identify patients that underwent undergoing primary and revision posterior lumbar fusion from 2005 to 2013. The occurrence of individual and aggregated postoperative complications within 30 days, along with rates of blood transfusion and readmission, were compared between primary and revision procedures using bivariate and multivariate Poisson regression with robust error variance to control for patient and operative characteristics. Operative time and postoperative length of stay were compared between groups using bivariate and multivariate linear regression.
RESULTS: Of the 14,873 posterior lumbar fusion procedures that met inclusion criteria, 1287 (8.7%) were revision cases. There were no differences in the rates of 30-day postoperative complications or readmission between primary and revision posterior lumbar fusion using multivariate analysis to control for patient and operative characteristics. Similarly, no significant differences were found for operative time or postoperative length of stay. There was an increased rate of blood transfusion for revision surgery compared with primary surgery (relative risk 1.4, P < 0.001).
CONCLUSION: This study suggests that revision posterior lumbar fusion does not carry significantly increased risk of complications or readmission compared with a primary posterior lumbar fusion. Patients undergoing revision surgery were more likely to receive a blood transfusion. This information suggests that general health risk stratification for revision procedures can be similar to that considered for primary cases. LEVEL OF EVIDENCE: 3.

Entities:  

Mesh:

Year:  2016        PMID: 26539938     DOI: 10.1097/BRS.0000000000001094

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  4 in total

Review 1.  Stem cell therapy in discogenic back pain.

Authors:  Ahmed H Barakat; Vivian A Elwell; Khai S Lam
Journal:  J Spine Surg       Date:  2019-12

2.  Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy.

Authors:  Christopher Centeno; Jason Markle; Ehren Dodson; Ian Stemper; Christopher J Williams; Matthew Hyzy; Thomas Ichim; Michael Freeman
Journal:  J Transl Med       Date:  2017-09-22       Impact factor: 5.531

3.  Revision Surgery after Percutaneous Endoscopic Transforaminal Discectomy Compared with Primary Open Surgery for Symptomatic Lumbar Degenerative Disease.

Authors:  Jin-Qian Liang; Chong Chen; Hong Zhao
Journal:  Orthop Surg       Date:  2019-08-11       Impact factor: 2.071

4.  The incidence of stroke among selected patients undergoing elective posterior lumbar fusion: a retrospective cohort study.

Authors:  Patrick J Arena; Jingping Mo; Charu Sabharwal; Elizabeth Begier; Xiaofeng Zhou; Alejandra Gurtman; Qing Liu; Rongjun Shen; Charles Wentworth; Kui Huang
Journal:  BMC Musculoskelet Disord       Date:  2020-09-14       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.